Literature DB >> 24928051

Production and characterization of high-titer serum-free cell culture grown hepatitis C virus particles of genotype 1-6.

Christian K Mathiesen1, Tanja B Jensen1, Jannick Prentoe1, Henrik Krarup2, Alfredo Nicosia3, Mansun Law4, Jens Bukh1, Judith M Gottwein5.   

Abstract

Recently, cell culture systems producing hepatitis C virus particles (HCVcc) were developed. Establishment of serum-free culture conditions is expected to facilitate development of a whole-virus inactivated HCV vaccine. We describe generation of genotype 1-6 serum-free HCVcc (sf-HCVcc) from Huh7.5 hepatoma cells cultured in adenovirus expression medium. Compared to HCVcc, sf-HCVcc showed 0.6-2.1 log10 higher infectivity titers (4.7-6.2 log10 Focus Forming Units/mL), possibly due to increased release and specific infectivity of sf-HCVcc. In contrast to HCVcc, sf-HCVcc had a homogeneous single-peak density profile. Entry of sf-HCVcc depended on HCV co-receptors CD81, LDLr, and SR-BI, and clathrin-mediated endocytosis. HCVcc and sf-HCVcc were neutralized similarly by chronic-phase patient sera and by human monoclonal antibodies targeting conformational epitopes. Thus, we developed serum-free culture systems producing high-titer single-density sf-HCVcc, showing similar biological properties as HCVcc. This methodology has the potential to advance HCV vaccine development and to facilitate biophysical studies of HCV.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adenovirus expression medium; Biophysical characterization; Cell culture system; Genotypes; Hepatitis C virus; High-titer; Neutralization; Receptor blocking; Serum-free; Vaccine development

Mesh:

Substances:

Year:  2014        PMID: 24928051      PMCID: PMC4415741          DOI: 10.1016/j.virol.2014.03.021

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  77 in total

Review 1.  Hepatitis C virus host cell entry.

Authors:  Alexander Ploss; Matthew J Evans
Journal:  Curr Opin Virol       Date:  2012-01-04       Impact factor: 7.090

2.  Reconstitution of the entire hepatitis C virus life cycle in nonhepatic cells.

Authors:  Daniel Da Costa; Marine Turek; Daniel J Felmlee; Erika Girardi; Sébastien Pfeffer; Gang Long; Ralf Bartenschlager; Mirjam B Zeisel; Thomas F Baumert
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

3.  Production and characterization of HCV particles from serum-free culture.

Authors:  Daisuke Akazawa; Kenichi Morikawa; Noriaki Omi; Hitoshi Takahashi; Noriko Nakamura; Hidenori Mochizuki; Tomoko Date; Koji Ishii; Tetsuro Suzuki; Takaji Wakita
Journal:  Vaccine       Date:  2011-05-07       Impact factor: 3.641

4.  Identification of alpha interferon-induced envelope mutations of hepatitis C virus in vitro associated with increased viral fitness and interferon resistance.

Authors:  Stéphanie B N Serre; Henrik B Krarup; Jens Bukh; Judith M Gottwein
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

5.  Cell entry, efficient RNA replication, and production of infectious hepatitis C virus progeny in mouse liver-derived cells.

Authors:  Anne Frentzen; Engin Gürlevik; Kathrin Hueging; Sarah Knocke; Corinne Ginkel; Richard J P Brown; Markus Heim; Michael T Dill; Andrea Kröger; Ulrich Kalinke; Lars Kaderali; Florian Kuehnel; Thomas Pietschmann
Journal:  Hepatology       Date:  2013-11-18       Impact factor: 17.425

6.  Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture.

Authors:  Kyung-Soo Chang; Jieyun Jiang; Zhaohui Cai; Guangxiang Luo
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

7.  Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization.

Authors:  Troels K H Scheel; Judith M Gottwein; Tanja B Jensen; Jannick C Prentoe; Anne M Hoegh; Harvey J Alter; Jesper Eugen-Olsen; Jens Bukh
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-14       Impact factor: 11.205

8.  The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding.

Authors:  K H Weisgraber; T L Innerarity; K J Harder; R W Mahley; R W Milne; Y L Marcel; J T Sparrow
Journal:  J Biol Chem       Date:  1983-10-25       Impact factor: 5.157

Review 9.  Cell culture systems for hepatitis C virus.

Authors:  Eike Steinmann; Thomas Pietschmann
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

10.  Expression of heterologous proteins flanked by NS3-4A cleavage sites within the hepatitis C virus polyprotein.

Authors:  Joshua A Horwitz; Marcus Dorner; Tamar Friling; Bridget M Donovan; Alexander Vogt; Joana Loureiro; Thomas Oh; Charles M Rice; Alexander Ploss
Journal:  Virology       Date:  2013-02-26       Impact factor: 3.616

View more
  8 in total

1.  Patch-Clamp Study of Hepatitis C p7 Channels Reveals Genotype-Specific Sensitivity to Inhibitors.

Authors:  Ulrike Breitinger; Noha S Farag; Nourhan K M Ali; Hans-Georg A Breitinger
Journal:  Biophys J       Date:  2016-06-07       Impact factor: 4.033

2.  Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.

Authors:  Lisa N Wasilewski; Stuart C Ray; Justin R Bailey
Journal:  J Gen Virol       Date:  2016-09-21       Impact factor: 3.891

3.  Adaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based Recombinant.

Authors:  Christian K Mathiesen; Jannick Prentoe; Luke W Meredith; Tanja B Jensen; Henrik Krarup; Jane A McKeating; Judith M Gottwein; Jens Bukh
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

4.  High density Huh7.5 cell hollow fiber bioreactor culture for high-yield production of hepatitis C virus and studies of antivirals.

Authors:  Anne F Pihl; Anna F Offersgaard; Christian K Mathiesen; Jannick Prentoe; Ulrik Fahnøe; Henrik Krarup; Jens Bukh; Judith M Gottwein
Journal:  Sci Rep       Date:  2018-11-30       Impact factor: 4.379

5.  High-Titer Hepatitis C Virus Production in a Scalable Single-Use High Cell Density Bioreactor.

Authors:  Anna Offersgaard; Carlos Rene Duarte Hernandez; Anne Finne Pihl; Nandini Prabhakar Venkatesan; Henrik Krarup; Xiangliang Lin; Udo Reichl; Jens Bukh; Yvonne Genzel; Judith Margarete Gottwein
Journal:  Vaccines (Basel)       Date:  2022-02-07

6.  Human Immunodeficiency Viruses Pseudotyped with SARS-CoV-2 Spike Proteins Infect a Broad Spectrum of Human Cell Lines through Multiple Entry Mechanisms.

Authors:  Chuan Xu; Annie Wang; Ke Geng; William Honnen; Xuening Wang; Natalie Bruiners; Sukhwinder Singh; Fortunato Ferrara; Sara D'Angelo; Andrew R M Bradbury; Maria Laura Gennaro; Dongfang Liu; Abraham Pinter; Theresa L Chang
Journal:  Viruses       Date:  2021-05-21       Impact factor: 5.048

7.  Antibodies Targeting Novel Neutralizing Epitopes of Hepatitis C Virus Glycoprotein Preclude Genotype 2 Virus Infection.

Authors:  Kai Deng; Ruyu Liu; Huiying Rao; Dong Jiang; Jianghua Wang; Xingwang Xie; Lai Wei
Journal:  PLoS One       Date:  2015-09-25       Impact factor: 3.240

8.  Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccine.

Authors:  Keven Lothert; Anna F Offersgaard; Anne F Pihl; Christian K Mathiesen; Tanja B Jensen; Garazi Peña Alzua; Ulrik Fahnøe; Jens Bukh; Judith M Gottwein; Michael W Wolff
Journal:  Sci Rep       Date:  2020-10-01       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.